Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Cyclically Adjusted Revenue per Share: ¥10.59 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600267 Zhejiang Hisun Pharmaceutical Co Ltd SHSE:600267
54 GF Score
Price ¥13.08
GF Value ¥8.72
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Zhejiang Hisun Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Zhejiang Hisun Pharmaceutical Co SHSE:600267 -6.70% 54 Cyclically Adjusted Revenue per Share is ¥10.59 as of Mar. 2026. GuruFocus rates SHSE:600267 with a GF Score™ of 54/100 and a GF Value™ of ¥8.72 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zhejiang Hisun Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥2.083. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥10.59 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zhejiang Hisun Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 1.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zhejiang Hisun Pharmaceutical Co was 17.40% per year. The lowest was -3.00% per year. And the median was 8.60% per year.

As of today (2026-08-21), Zhejiang Hisun Pharmaceutical Co's current stock price is ¥13.08. Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥10.59. Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Hisun Pharmaceutical Co was 1.89. The lowest was 0.63. And the median was 1.10.


Zhejiang Hisun Pharmaceutical Co  (SHSE:600267) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.08/10.59
=1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Hisun Pharmaceutical Co was 1.89. The lowest was 0.63. And the median was 1.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zhejiang Hisun Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Zhejiang Hisun Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Hisun Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Zhejiang Hisun Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.33 11.63 11.19 10.74 10.61

Zhejiang Hisun Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.46 10.49 10.54 10.61 10.59

SHSE:600267 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Hisun Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600267
54GF Score
Zhejiang Hisun Pharmaceutical Co Ltd SHSE:600267
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Hisun Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zhejiang Hisun Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.083/116.3033*116.3033
=2.083

Current CPI (Mar. 2026) = 116.3033.

Zhejiang Hisun Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.537 101.400 2.910
201609 2.689 102.400 3.054
201612 2.755 102.600 3.123
201703 2.805 103.200 3.161
201706 2.903 103.100 3.275
201709 2.864 104.100 3.200
201712 1.766 104.500 1.965
201803 2.876 105.300 3.177
201806 2.514 104.900 2.787
201809 2.559 106.600 2.792
201812 2.928 106.500 3.198
201903 2.909 107.700 3.141
201906 3.012 107.700 3.253
201909 2.740 109.800 2.902
201912 3.338 111.200 3.491
202003 2.590 112.300 2.682
202006 2.912 110.400 3.068
202009 2.951 111.700 3.073
202012 3.244 111.500 3.384
202103 2.904 112.662 2.998
202106 2.479 111.769 2.580
202109 2.528 112.215 2.620
202112 2.060 113.108 2.118
202203 2.424 114.335 2.466
202206 2.252 114.558 2.286
202209 2.537 115.339 2.558
202212 2.199 115.116 2.222
202303 2.242 115.116 2.265
202306 2.585 114.558 2.624
202309 2.232 115.339 2.251
202312 1.119 114.781 1.134
202403 2.304 115.227 2.326
202406 2.153 114.781 2.182
202409 2.267 115.785 2.277
202412 2.219 114.893 2.246
202503 2.304 115.116 2.328
202506 2.261 114.907 2.288
202509 2.311 115.471 2.328
202512 2.110 115.832 2.119
202603 2.083 116.303 2.083

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥10.59 mean?
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a Cyclically Adjusted Revenue per Share of ¥10.59 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors.
Is Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Zhejiang Hisun Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥10.59. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Zhejiang Hisun Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥10.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. Zhejiang Hisun Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥10.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.72, compared to a current price of ¥13.08 — trading 50% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥10.59. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current Cyclically Adjusted Revenue per Share is ¥10.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥13.08 is trading 50% above its estimated GF Value™ of ¥8.72. GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:600267:

  • Cyclically Adjusted Revenue per Share: ¥10.59
  • GF Value™: ¥8.72 vs. price of ¥13.08 (50% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Hisun Pharmaceutical Co Business Description

Address No. 46 Waisha Road, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
54GF Score

Get the complete analysis for SHSE:600267

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥13.08
Price
¥8.72
GF Value